Why is ResMed stock rallying today?
ResMed (RMD) stock rose 2.9% after providing fiscal 2027 guidance, projecting 5%-7% revenue growth and 12%-14% EPS growth. RBC upgraded RMD to Outperform, raising its price target to $262. Despite broader market declines, RMD's positive outlook resonated with investors, addressing concerns about GLP-1 headwinds and competition.
How this was made
The 30-second read
Why it matters
The guidance and upgrade provide a clear catalyst for short‑term buying, with upside potential if growth targets are met.
Market read
ResMed's stock rally contrasts with broader market declines, highlighting the impact of company‑specific guidance.
What to watch
Potential headwinds from the Astral field safety notice and macro‑rate environment.
Background
ResMed's guidance was presented at the Morgan Stanley Global Healthcare Conference amid a risk‑off market environment.
Ticker impact
ResMed delivered its first formal fiscal 2027 guidance and received an analyst upgrade, driving a 2.9% price rise.
Potential upside of 5‑7% over the next 3‑6 months if guidance holds.
Guidance numbers exceed prior expectations and the upgrade raises target price, indicating near‑term buying interest.
Market effects
Positive signal for the sleep‑apnea and broader medical device sector.
U.S. healthcare stocks may see modest gains.
Limited to investors tracking US med‑tech equities.
Counterpoint
Guidance may be optimistic given upcoming GLP‑1 competition; price could be overstated.
Key entities
- CompanyResMed Inc.
Medical device maker specializing in sleep‑apnea equipment.
- AnalystRBC Capital Markets
Upgraded ResMed to Outperform and raised price target.
